Research
Mixed
Obesity pharmacotherapy is recommended against for compounded medications or unapproved medications due to safety and efficacy concerns.
Avoid compounded weight loss medications. They are not approved, may be unsafe, and are not proven to work. Stick to FDA/Health Canada-approved medications prescribed by your doctor.
GoodRefutesHIGH confidence
We recommend against the use of compounded medications, prescription medications, or over-the-counter medications other than those approved in Canada for weight loss in people with excess adiposity.
Why this rating
Level 4 evidence (consensus/expert opinion) based on lack of data for compounded products.
Source
Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update
Sue D. Pedersen et al. · Canadian Medical Association Journal · 2025
DOI 10.1503/cmaj.250502
clinical_guidelineCited 32×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-term use of FDA/Health Canada-approved obesity pharmacotherapies (semaglutide, tirzepatide, liraglutide, naltrexone-bupropion, orlistat) combined with health behavior changes produces clinically meaningful weight loss and prevents weight regain upon discontinuation.Weak
- Tirzepatide (5-15 mg weekly) produces superior weight loss compared to semaglutide and placebo in adults with obesity, with dose-dependent efficacy.Weak
- Obesity pharmacotherapy reduces the risk of major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and BMI ≥ 27, independent of diabetes status.Weak
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →